Format

Send to

Choose Destination
Br J Clin Pharmacol. 2007 Dec;64(6):785-91. Epub 2007 Jul 27.

Effect of dronedarone on renal function in healthy subjects.

Author information

1
Clinical Pharmacology and Toxicology, University Hospital, Lausanne, Switzerland.

Abstract

AIMS:

To assess the effects of dronedarone on renal function and tubular cation handling.

METHODS:

Twelve healthy males were enrolled in a randomized, cross-over, placebo-controlled, double-blind study. They received 400 mg dronedarone or placebo twice daily for 7 days. Baseline and on-treatment renal function tests were performed under strict standardization of intakes, by assessing creatinine, sinistrin, para-amino-hippurate (PAH) and N-methylnicotinamide (NMN) CLs, and electrolyte excretion.

RESULTS:

Compared with placebo, dronedarone significantly decreased renal creatinine CL (mean 138-119 ml min(-1) after dronedarone vs. 142-149 ml min(-1) after placebo) and NMN CL (448-368 ml min(-1)vs. 435-430 ml min(-1)), but did not alter renal sinistrin CL, PAH CL and other renal parameters.

CONCLUSIONS:

Dronedarone reduces renal creatinine and NMN clearance by about 18%, without evidence of an effect on GFR, renal plasma flow or electrolyte exchanges. This suggests a specific partial inhibition of tubular organic cation transporters (OCT). A limited increase in serum creatinine is therefore expected with dronedarone treatment, but does not mean there is a decline in renal function.

PMID:
17662087
PMCID:
PMC2198776
DOI:
10.1111/j.1365-2125.2007.02998.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center